Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Non-Current Deferred Tax Liability (2022 - 2024)

Sunshine Biopharma (SBFM) has disclosed Non-Current Deferred Tax Liability for 3 consecutive years, with $389513.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Non-Current Deferred Tax Liability rose 72.74% year-over-year to $389513.0, compared with a TTM value of $389513.0 through Dec 2024, up 72.74%, and an annual FY2024 reading of $389513.0, up 72.74% over the prior year.
  • Non-Current Deferred Tax Liability was $389513.0 for Q4 2024 at Sunshine Biopharma, up from $48729.0 in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $389513.0 in Q4 2024 and bottomed at $43032.0 in Q4 2022.
  • Average Non-Current Deferred Tax Liability over 3 years is $103702.3, with a median of $48729.0 recorded in 2024.
  • The sharpest move saw Non-Current Deferred Tax Liability soared 424.01% in 2023, then increased 13.24% in 2024.
  • Year by year, Non-Current Deferred Tax Liability stood at $43032.0 in 2022, then skyrocketed by 424.01% to $225493.0 in 2023, then surged by 72.74% to $389513.0 in 2024.
  • Business Quant data shows Non-Current Deferred Tax Liability for SBFM at $389513.0 in Q4 2024, $48729.0 in Q3 2024, and $48729.0 in Q2 2024.